Abstract
Heart failure (HF) is becoming a major health problem in developing and already-developed countries that requires more investment in human and physical resources. Taking Brazil, the largest country in Latin America, as representative of the continent, cardiovascular diseases are responsible for almost 30% of annual deaths. It is estimated that one third of these deaths are due to HF. These data are relevant, since they demonstrate that this syndrome is one of the main causes of death in this part of the world and consequently demand more attention from the medical community and public health authorities1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mansur AP, Souza MFM, Timerman A, Ramires JAF. Tendência do risco de morte por doenças circulatórias, cerebrovasculares e isquêmicas do coração em 11 capitais do Brasil de 1980 a 1998. Arq Bras Cardiol 2002;79:269–276.
Dias JCP, Silveira AC, Schofield CJ. The impact of Chagas’ disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002;97(5):603–612.
Shulman IA, Appleman MD, Saxena S, Hiti AL, Kirchhoff LV. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 1997;37:727–731.
Bocchi EA, Vilas-Boas F, Perrone S, et al. 1st Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure. Arq Bras Cardiol 2005;85(suppl 3):1–94.
Pereira-Barretto AC, Rassi S, Vilas-Boas F, et al., for the Brazilian Evaluation of Levosimendan Infusion Efficacy (BELIEF) study investigators. Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies. Crit Care 2003;7(suppl 3):P23.
Rassi Jr A, Rassi A, Little WC. Chagas’ heart disease. Clin Cardiol 2000;23:883–889.
Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003;98(5):577–591.
Coll-Cardenas R, Espinoza-Gomez F, Maldonado-Rodriguez A, Reyes-Lopez PA, Huerta-Viera M, Rojas-Larios F. Active transmission of human Chagas disease in Colima Mexico. Mem Inst Oswaldo Cruz 2004;99(4):363–368.
Nowicki MJ, Chinchilla C, Corado L, et al. Prevalence of antibodies to Trypanosoma cruzi among solid organ donors in Southern California: a population at risk. Transplantation 2006;81:477–479.
Prata A. Clinical and epidemiological apects of Chagas disease. Lancet Infect Dis 2000;1:92–100.
Bocchi EA, Bellotti G, Mocelin A, et al. Heart transplantation for chronic Chagas heart disease. Ann Thorac Surg 1996;61:1727–1733.
Alemida IC, Salles NA, Santos MLP, et al. Serum diagnosis of American trypanosomiasis in blood bank: a highly sensitive and specific carbohydrate rich trypomastigotes antigen and why there are so many inconclusive results. Mem Inst Oswaldo Cruz 1995;90(suppl):72–74.
Bezerra de Melo R, Parente GBO, Victor EG. Measurement of human brain natriuretic. Peptide in patients with Chagas’ disease. Arq Bras Cardiol 2005;84(2):137–140.
Talvani A, Rocha MOC, Cogan J, et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz 2004;99(6):645–649.
Vilas-Boas F, Follath F. Current insights into the modern treatment of decompensated heart failure. Arq Bras Cardiol 2006;87:329–337.
Garrido M, Castano R, Antonio J, Estrada J, Gaxiola A. Levosimendan reduces length of hospital stay for patients with acutely decompensated heart failure. Eur J Heart Fail 2003;2(suppl 1):163(abstr).
Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med 2006;16;144(10):772–774.
Andrade ALS, Zicker F, Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348:1407–1413.
Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. A nonrandomized trial. Ann Intern Med 2006;144:724–734.
Vilas-Boas F, Feitosa GS, Soares MBP, et al. Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease. Arq Bras Cardiol 2006;87:545–552.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Vilas-Boas, F. (2008). Peculiarities of Acute Heart Failure Syndromes in Latin America and the Role of Chagas’ Disease. In: Mebazaa, A., Gheorghiade, M., Zannad, F.M., Parrillo, J.E. (eds) Acute Heart Failure. Springer, London. https://doi.org/10.1007/978-1-84628-782-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-84628-782-4_5
Publisher Name: Springer, London
Print ISBN: 978-1-84628-781-7
Online ISBN: 978-1-84628-782-4
eBook Packages: MedicineMedicine (R0)